相似文献
1
Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells.
Cancer Immunol Immunother. 2005 Aug;54(8):807-14. doi: 10.1007/s00262-004-0642-5. Epub 2005 Jan 21.
2
Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes.
Gynecol Oncol. 2004 Dec;95(3):488-95. doi: 10.1016/j.ygyno.2004.07.052.
3
Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis.
Gynecol Oncol. 2005 Feb;96(2):462-9. doi: 10.1016/j.ygyno.2004.10.024.
4
Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer.
FEBS Lett. 2005 Feb 14;579(5):1311-9. doi: 10.1016/j.febslet.2005.01.026. Epub 2005 Jan 26.
5
Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Clin Cancer Res. 2005 Feb 1;11(3):1010-20.
6
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
FEBS Lett. 2006 Jan 23;580(2):443-9. doi: 10.1016/j.febslet.2005.12.033. Epub 2005 Dec 20.
7
Epithelial ovarian cancer cells secrete functional Fas ligand.
Cancer Res. 2003 Sep 1;63(17):5573-81.
8
Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.
Cancer Res. 2010 Dec 1;70(23):9979-90. doi: 10.1158/0008-5472.CAN-10-2394. Epub 2010 Nov 30.
9
Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand.
J Immunol. 2003 Jan 15;170(2):677-85. doi: 10.4049/jimmunol.170.2.677.
10
Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.
Int J Oncol. 2005 Feb;26(2):379-84.
引用本文的文献
1
A game of hide-and-seek: how extracellular vesicles evade the immune system.
Drug Deliv Transl Res. 2025 Jan 22. doi: 10.1007/s13346-025-01789-w.
2
Recent Progress in the Application of Exosome Analysis in Ovarian Cancer Management.
Curr Cancer Drug Targets. 2024;24(9):920-929. doi: 10.2174/0115680096281906231213055422.
3
Immunosuppressive Extracellular Vesicles as a Linking Factor in the Development of Tumor and Endometriotic Lesions in the Gynecologic Tract.
Cells. 2022 Apr 28;11(9):1483. doi: 10.3390/cells11091483.
4
Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications.
Cells. 2021 Sep 1;10(9):2272. doi: 10.3390/cells10092272.
5
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy.
Cancers (Basel). 2020 Sep 30;12(10):2825. doi: 10.3390/cancers12102825.
6
Analogies Between Cancer-Derived Extracellular Vesicles and Enveloped Viruses with an Emphasis on Human Breast Cancer.
Curr Pathobiol Rep. 2016;4(4):169-179. doi: 10.1007/s40139-016-0116-4. Epub 2016 Aug 27.
7
The role of microvesicles and its active molecules in regulating cellular biology.
J Cell Mol Med. 2019 Dec;23(12):7894-7904. doi: 10.1111/jcmm.14667. Epub 2019 Sep 27.
8
Exosomes promote pre-metastatic niche formation in ovarian cancer.
Mol Cancer. 2019 Aug 13;18(1):124. doi: 10.1186/s12943-019-1049-4.
9
Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target.
Cancers (Basel). 2019 Aug 10;11(8):1147. doi: 10.3390/cancers11081147.
10
The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer.
Mol Cancer. 2017 May 15;16(1):92. doi: 10.1186/s12943-017-0659-y.
本文引用的文献
1
Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes.
Gynecol Oncol. 2004 Dec;95(3):488-95. doi: 10.1016/j.ygyno.2004.07.052.
2
The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack.
Exp Cell Res. 2004 May 1;295(2):315-29. doi: 10.1016/j.yexcr.2003.12.024.
3
Slowly getting a clue on CD95 ligand biology.
Biochem Pharmacol. 2003 Oct 15;66(8):1417-26. doi: 10.1016/s0006-2952(03)00492-1.
4
Epithelial ovarian cancer cells secrete functional Fas ligand.
Cancer Res. 2003 Sep 1;63(17):5573-81.
5
Microtubule-dependent transport of secretory vesicles in RBL-2H3 cells.
Traffic. 2003 May;4(5):302-12. doi: 10.1034/j.1600-0854.2003.00084.x.
6
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex.
Mol Cell Biol. 2003 Feb;23(4):1428-40. doi: 10.1128/MCB.23.4.1428-1440.2003.
7
Lysophosphatidic acid is a bioactive mediator in ovarian cancer.
Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64. doi: 10.1016/s1388-1981(02)00179-8.
8
The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities.
J Biochem. 2002 Jun;131(6):767-71. doi: 10.1093/oxfordjournals.jbchem.a003163.
9
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.
J Exp Med. 2002 May 20;195(10):1303-16. doi: 10.1084/jem.20011624.
10
Secretory lysosomes.
Nat Rev Mol Cell Biol. 2002 Feb;3(2):122-31. doi: 10.1038/nrm732.
Zotero 插件